Melanoma-associated tumor-associated antigen (MAA)

Melanoma-associated tumor-associated antigens (MAAs) are a diverse group of proteins expressed by melanoma cells that serve as targets for the immune system. These antigens are broadly categorized into melanocyte differentiation antigens (e.g., gp100, MART-1), cancer-testis antigens (e.g., MAGE family, NY-ESO-1), and overexpressed antigens (e.g., PRAME) [1, 2]. While differentiation antigens are also found in normal melanocytes, cancer-testis antigens are typically restricted to tumor cells and immune-privileged germ cells, making them highly attractive for targeted therapy [2, 4]. In the context of indirect immune targets, these molecules are not usually inhibited by small molecules but are instead targeted by immunotherapies such as vaccines, T-cell receptor (TCR) engineered T-cells, and bispecific T-cell engagers (BiTEs) [3, 5]. These therapies aim to overcome the tumor's immune evasion mechanisms by directing cytotoxic T lymphocytes to recognize and destroy cells presenting these antigenic peptides on their surface via major histocompatibility complex (MHC) molecules [1, 3]. Clinical success has been seen with agents like tebentafusp, which targets gp100, and various TCR-T therapies targeting MAGE-A4 and NY-ESO-1 [5].

Other names

Melanoma-associated antigenTumor-associated antigen (TAA)Melanoma-specific antigenCancer-testis antigen (CTA)Melanocyte differentiation antigen

Induction of antigen-specific T-cell mediated cytotoxicity, T-cell redirection via bispecific molecules, or direct targeting by antibody-drug conjugates.